Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
hepatitis C
Biotech
Atea’s hepatitis C asset matches Gilead’s Epclusa in phase 3
The phase 3 data keep Atea barreling toward a second readout for its shorter, simpler treatment regimen.
Nick Paul Taylor
Jul 28, 2026 9:08am
Atea offloads 25% of workforce, gears up for phase 3 HCV trials
Mar 7, 2025 5:50am
AI drug discoverer's antiviral reduces COVID in mouse lungs
Jan 21, 2025 12:42am
Atea's COVID antiviral fails to halt hospitalizations in phase 3
Sep 13, 2024 10:10am
FDA clears its first fingerstick hepatitis C diagnostic test
Jul 2, 2024 11:04am
FDA unlocks faster clearances for future hepatitis C diagnostics
Nov 22, 2021 11:21am
